Succeeding the identification and characterization of highly cytotoxic, terminally differentiated CD8 T cells [16, 18], renewed attention has been focused on the development of immunomodulatory strategies for IBM, e.g. the depletion of KLRG1+ CD8 T cells [14]. The gene discussed is CD8A; the disease is inclusion body myositis.